Amgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in a legal tussle with Sandoz over the patent covering the blockbuster inflammatory diseases ...
Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback